Oppenheimer Asset Management Inc. Sage Therapeutics, Inc. Transaction History

Oppenheimer Asset Management Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 08, 2020	SELL	$26.15 - $77.24 $41,003 - $121,112	-1,568 Closed	0 $0
Q4 2019 Feb 07, 2020	SELL	$60.18 - $154.77 $176,267 - $453,321	-2,929 Reduced 65.13%	1,568 $113,000
Q3 2019 Oct 31, 2019	SELL	$140.29 - $189.96 $31,565 - $42,741	-225 Reduced 4.76%	4,497 $631,000
Q2 2019 Aug 09, 2019	SELL	$157.85 - $183.09 $22,572 - $26,181	-143 Reduced 2.94%	4,722 $865,000
Q1 2019 Apr 24, 2019	BUY	$89.33 - $163.65 $78,074 - $143,030	874 Added 21.9%	4,865 $774,000
Q4 2018 Jan 30, 2019	SELL	$81.94 - $139.71 $26,876 - $45,824	-328 Reduced 7.59%	3,991 $382,000
Q3 2018 Oct 26, 2018	BUY	$138.11 - $169.04 $52,067 - $63,728	377 Added 9.56%	4,319 $610,000
Q2 2018 Aug 10, 2018	BUY	$140.36 - $175.76 $261,069 - $326,913	1,860 Added 89.34%	3,942 $617,000
Q1 2018 May 09, 2018	BUY	$152.15 - $192.33 $316,776 - $400,431	2,082 New	2,082 $335,000
Q4 2017 Feb 07, 2018	SELL	$60.72 - $167.34 $118,039 - $325,308	-1,944 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $119,361 - $172,082	1,944	1,944 $122,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.